Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 6767 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. FDA to evaluate increased risk of heart -related death and death from all causes with the gout medicine febuxostat (Uloric). FDA U.S. Food and Drug Administration 2017:15 de noviembre. [Ref.ID 102144]
2. Cita con resumen
Anónimo. FDA approves first digital pill. DIA Daily 2017:1. [Ref.ID 102142]
3. Cita con resumen
Wilke RA, Freeman JW. Potential health implications related to fracking. JAMA 2017;318:1645-6. [Ref.ID 102135]
5. Cita con resumen
Burcu M, Zito JM, Safer DJ, Magder LS, dos-Reis S, Shaya FT, Rosenthal GL. Association of antidepressant medications with incident type 2 diabetes among Medicaid-insured youths. JAMA Pediatrics 2017:16 de octubre. [Ref.ID 102122]
7.Tiene citas relacionadas Cita con resumen
Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. BMJ 2017;359:j4619. [Ref.ID 102108]
8.Tiene citas relacionadas Cita con resumen
Socías ME, Wood E. Epidemic of deaths from fentanyl overdose. BMJ 2017;359:j4355. [Ref.ID 102107]
9.Tiene citas relacionadas Cita con resumen
Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ 2017;359:j4792. [Ref.ID 102106]
10.Tiene citas relacionadas Cita con resumen
O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden M. Deaths involving fentanyl, fentanyl analogs, and U-47700 — 10 states, July–December 2016. Morbidity and Mortality Weekly Report 2017;66:1-5. [Ref.ID 102103]
12. Cita con resumen
Casassus B. Contraception implant removed from global market. Lancet 2017;390:1576. [Ref.ID 102079]
13. Cita con resumen
Edwards IR. A new Erice report considering the safety of medicines in the 21st Century. Drug Saf 2017;40:845-9. [Ref.ID 102074]
14. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
16.Tiene citas relacionadas Cita con resumen
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thompson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, for the WHI Investigators. Menopausal Hormone therapy and long-term all-cause and cause-specific mortality. The Women’s Health Initiative randomized trials. JAMA 2017;318:927-38. [Ref.ID 102070]
17.Tiene citas relacionadas Cita con resumen
McNeil M. Menopausal hormone therapy. Understanding long-term risks and benefits. JAMA 2017;318:911-3. [Ref.ID 102069]
18. Cita con resumen
Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf 2017;26:1083-7. [Ref.ID 102063]
19. Cita con resumen
Anónimo. Statines: lombalgies. Prescrire 2017;37:579. [Ref.ID 102059]
Seleccionar todas
 
 1 a 20 de 6767 siguiente >>